Guideline-Directed Medical Therapy for Heart Failure (HFrEF new quadruple therapy) — free guideline decision tool
This tool classifies heart failure by LVEF and frames the HFrEF 'new quadruple therapy' (ARNI + β-blocker + MRA + SGLT2i), with cautions by blood pressure, renal function, and potassium.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Common questions
What does Guideline-Directed Medical Therapy for Heart Failure (HFrEF new quadruple therapy) do?
Use to set the core regimen: HFrEF (LVEF ≤ 40%) starts all four pillars early, HFmrEF prefers an SGLT2i, and HFpEF centers on SGLT2i plus diuresis and comorbidity management.
How is the result calculated?
LVEF ≤ 40% → ARNI + β-blocker + MRA + SGLT2i titrated to target; 41–49% → SGLT2i preferred; ≥ 50% → SGLT2i + diuresis + comorbidities. Flags low SBP, K ≥ 5.0, and eGFR < 30.
Is this a substitute for clinical judgement?
No. All results are decision-support only, for licensed clinicians. They must be individualized to the whole patient and the latest guideline version.
Run Guideline-Directed Medical Therapy for Heart Failure (HFrEF new quadruple therapy) now
This tool classifies heart failure by LVEF and frames the HFrEF 'new quadruple therapy' (ARNI + β-blocker + MRA + SGLT2i), with cautions by blood pressure, renal function, and potassium.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.